drugset / Trial / NCT00639808

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis

NCT00639808

Phase 1 Completed 10 enrolled Tranzyme, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to determine whether TZP-101 is safe in people with diabetes. Also to determine if TZP-101 is effective in increasing the gastric emptying rate in diabetic patients.

Timeline

Start
2006-08
Primary completion
2007-07
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulimorelin Small molecule 160 ug/kg Intravenous
Subject Ulimorelin Small molecule 320 ug/kg Intravenous
Subject Ulimorelin Small molecule 600 ug/kg Intravenous